Sanofi India Ltd (SANOFI)
₹3,388.90
Mkt cap
₹7,777 Cr
P/E ratio
23.70
P/B
10.40
Div yield
2.22%
ROE
43.00%
ROCE
57.50%
EPS (TTM)
₹142.99
Book value
₹326
52W range
3,097–5,951
Sector
Healthcare
Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines. [1]
Health check
Mixed
ValuationCheap
ProfitabilityStrong
GrowthLow
TechnicalsBearish
52-week range
−43.05% from high₹3,389
₹3,097+9.42% from low₹5,951
Current
₹3,388.90
Prev close
₹3,402.90
Day
−0.41%
Price performance
1D
−0.41%
1W
−0.09%
1M
+0.99%
3M
−1.13%
6M
−16.36%
1Y
−43.25%
YTD
−18.18%
Financials
FRevenue, profit & margin
P/E ratio
23.7×
SANOFI is 32% below the sector median of 34.9×
SANOFI23.7×
Sector median34.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 | 420 | 472 | |
| Expenses | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 | 330 | 330 | |
| Operating Profit | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 | 90 | 143 | |
| OPM % | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% | 22% | 30% | |
| Other Income | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | -22 | 3 | 4 | |
| Interest | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | |
| Depreciation | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 | 10 | 9 | |
| Profit before tax | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 | 83 | 138 | |
| Tax % | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% | 26% | 26% | |
| Net Profit | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 | 62 | 103 | |
| EPS in Rs | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 | 33.04 | 26.83 | 44.61 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
4 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202660.40%Promoter
Promoters60.40%
FIIs5.65%0.10
DIIs21.12%0.18
Public12.84%0.09
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.68 | 4,68,230 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.49 | 1,69,825 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.05 | 1,13,988 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.28 | 1,05,029 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Sanofi India | ₹3,377.00 | 23.66 | 7,777 | 2.22% | 103 | −14.14% | 472 | −11.87% | 57.51% |
| Median: 156 Co. | ₹434.68 | 34.87 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2013nseFinancial Year 2012bse
Concall transcripts16
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Jul - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026.Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 3 Jul - Income tax appeal for AY2019-20 allowed; Rs. 72.71 lakh demand deleted.Closure of Trading Window 26 JunDisclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 24 Jun - Ahmedabad State GST rejected Sanofi India’s INR 11.63 lakh refund claim; company will appeal.Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 9 Jun - CGST authority dropped FY2018-19 tax demand of INR 10,56,954 for duplicate e-way bills.